BR112018072168A2 - compostos derivados da pirimidina como inibidores da quinase jak - Google Patents

compostos derivados da pirimidina como inibidores da quinase jak

Info

Publication number
BR112018072168A2
BR112018072168A2 BR112018072168-9A BR112018072168A BR112018072168A2 BR 112018072168 A2 BR112018072168 A2 BR 112018072168A2 BR 112018072168 A BR112018072168 A BR 112018072168A BR 112018072168 A2 BR112018072168 A2 BR 112018072168A2
Authority
BR
Brazil
Prior art keywords
compounds
kinase inhibitors
pyrimidine derivatives
jak kinase
inhibitors
Prior art date
Application number
BR112018072168-9A
Other languages
English (en)
Portuguese (pt)
Inventor
Hudson Ryan
Kozak Jennifer
Fleury Melissa
R. Fatheree Paul
Beausoleil Anne-Marie
D. PODESTO Dante
Huang Xiaojun
Original Assignee
Theravance Biopharma R&D Ip, Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theravance Biopharma R&D Ip, Llc filed Critical Theravance Biopharma R&D Ip, Llc
Publication of BR112018072168A2 publication Critical patent/BR112018072168A2/pt

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/02—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof
    • C07D451/04—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing not further condensed 8-azabicyclo [3.2.1] octane or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane; Cyclic acetals thereof with hetero atoms directly attached in position 3 of the 8-azabicyclo [3.2.1] octane or in position 7 of the 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/06—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D451/00—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof
    • C07D451/14—Heterocyclic compounds containing 8-azabicyclo [3.2.1] octane, 9-azabicyclo [3.3.1] nonane, or 3-oxa-9-azatricyclo [3.3.1.0<2,4>] nonane ring systems, e.g. tropane or granatane alkaloids, scopolamine; Cyclic acetals thereof containing 9-azabicyclo [3.3.1] nonane ring systems, e.g. granatane, 2-aza-adamantane; Cyclic acetals thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
BR112018072168-9A 2016-04-28 2017-04-27 compostos derivados da pirimidina como inibidores da quinase jak BR112018072168A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662328737P 2016-04-28 2016-04-28
US62/328,737 2016-04-28
PCT/US2017/029796 WO2017189822A1 (en) 2016-04-28 2017-04-27 Pyrimidine compounds as jak kinase inhibitors

Publications (1)

Publication Number Publication Date
BR112018072168A2 true BR112018072168A2 (pt) 2019-02-12

Family

ID=58672793

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112018072168-9A BR112018072168A2 (pt) 2016-04-28 2017-04-27 compostos derivados da pirimidina como inibidores da quinase jak

Country Status (20)

Country Link
US (3) US10028960B2 (cg-RX-API-DMAC10.html)
EP (1) EP3433253B1 (cg-RX-API-DMAC10.html)
JP (1) JP6881879B2 (cg-RX-API-DMAC10.html)
KR (1) KR102244257B1 (cg-RX-API-DMAC10.html)
CN (1) CN109071529B (cg-RX-API-DMAC10.html)
AU (1) AU2017258186B2 (cg-RX-API-DMAC10.html)
BR (1) BR112018072168A2 (cg-RX-API-DMAC10.html)
CA (1) CA3020506A1 (cg-RX-API-DMAC10.html)
CL (1) CL2018003060A1 (cg-RX-API-DMAC10.html)
CO (1) CO2018011408A2 (cg-RX-API-DMAC10.html)
DK (1) DK3433253T3 (cg-RX-API-DMAC10.html)
EA (1) EA035226B1 (cg-RX-API-DMAC10.html)
ES (1) ES2779880T3 (cg-RX-API-DMAC10.html)
IL (1) IL262386B (cg-RX-API-DMAC10.html)
MX (1) MX377180B (cg-RX-API-DMAC10.html)
PT (1) PT3433253T (cg-RX-API-DMAC10.html)
SG (1) SG11201809342YA (cg-RX-API-DMAC10.html)
TW (1) TWI726094B (cg-RX-API-DMAC10.html)
WO (1) WO2017189822A1 (cg-RX-API-DMAC10.html)
ZA (1) ZA201807179B (cg-RX-API-DMAC10.html)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2924698T3 (es) 2015-05-28 2022-10-10 Theravance Biopharma R&D Ip Llc Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
EP3831830A1 (en) 2015-11-03 2021-06-09 Topivert Pharma Limited 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridine and 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepine derivatives as janus kinase inhibitors
DK3712152T3 (da) 2015-11-03 2021-03-22 Topivert Pharma Ltd 4,5,6,7-tetrahydro-1h-imidazo[4,5-c]pyridin og 1,4,5,6,7,8-hexahydroimidazo[4,5-d]azepinderivater som janus kinase-inhibitorer
WO2017189822A1 (en) * 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors
MA49956B1 (fr) 2017-10-27 2022-11-30 Theravance Biopharma R&D Ip Llc Composés de pyrimidine utilisés en tant qu'inhibiteurs de kinase jak
US12171764B2 (en) 2018-06-20 2024-12-24 Biora Therapeutics, Inc. Treatment of a disease of the gastrointestinal tract with a JAK or other kinase inhibitor
TWI740288B (zh) * 2018-11-27 2021-09-21 大陸商江蘇豪森藥業集團有限公司 含氮雜芳類衍生物調節劑、其製備方法和應用
CN115925705B (zh) * 2018-11-30 2024-12-31 江苏豪森药业集团有限公司 杂芳类衍生物调节剂、其制备方法和应用
JP7482152B2 (ja) * 2019-04-24 2024-05-13 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー 皮膚疾患の処置のためのピリミジンjak阻害剤 発明の背景
JP7470713B2 (ja) * 2019-04-24 2024-04-18 セラヴァンス バイオファーマ アール&ディー アイピー, エルエルシー Jakキナーゼ阻害剤としてのエステルおよびカルボナートピリミジン化合物
TW202207918A (zh) * 2020-05-14 2022-03-01 美商施萬生物製藥研發Ip有限責任公司 腸道選擇性jak3抑制劑的投與
TW202233636A (zh) * 2020-10-09 2022-09-01 美商賽若凡斯生物製藥研發智財有限責任公司 製備泛jak抑制劑之方法及相關中間化合物
WO2022083687A1 (zh) * 2020-10-21 2022-04-28 南京明德新药研发有限公司 硒杂环类化合物及其应用
WO2023011359A1 (zh) * 2021-08-05 2023-02-09 南京明德新药研发有限公司 桥环类化合物及其应用
CN113883920B (zh) * 2021-10-25 2024-01-23 安徽华铂再生资源科技有限公司 一种降低空分装置空冷塔出口温度的方法
WO2023202706A1 (zh) * 2022-04-21 2023-10-26 南京明德新药研发有限公司 硒杂环类化合物的盐型和晶型及其应用
WO2025040148A1 (zh) * 2023-08-22 2025-02-27 北京普祺医药科技股份有限公司 一种用于jak抑制剂的外用凝胶及其用途
TW202515852A (zh) * 2023-09-15 2025-04-16 美商莫菲克醫療股份有限公司 抑制人類整合素α4β7
US12684500B2 (en) 2024-01-17 2026-07-14 T-Mobile Usa, Inc. Dynamic scheduling request framework for HP UE SAR reduction

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6660731B2 (en) 2000-09-15 2003-12-09 Vertex Pharmaceuticals Incorporated Pyrazole compounds useful as protein kinase inhibitors
BR0116493A (pt) 2000-12-21 2003-09-30 Vertex Pharma Compostos de pirazol úteis como inibidores de proteìna cinase
US8211929B2 (en) * 2004-12-30 2012-07-03 Exelixis, Inc. Pyrimidine derivatives as kinase modulators and method of use
ATE508126T1 (de) 2005-11-16 2011-05-15 Vertex Pharma Als kinaseinhibitoren geeignete aminopyrimidine
TW200817391A (en) 2006-06-30 2008-04-16 Astrazeneca Ab Novel compounds
AU2007269540B2 (en) 2006-07-05 2013-06-27 Exelixis, Inc. Methods of using IGF1R and Abl kinase modulators
RU2014129740A (ru) 2011-12-22 2016-02-10 Ф.Хоффманн-Ля Рош Аг Производные 2,4-диаминопиримидина в качестве ингибиторов серин/треонин киназы
WO2015094803A1 (en) * 2013-12-16 2015-06-25 Calitor Sciences, Llc Substituted heteroaryl compounds and methods of use
NO2721710T3 (cg-RX-API-DMAC10.html) * 2014-08-21 2018-03-31
ES2924698T3 (es) 2015-05-28 2022-10-10 Theravance Biopharma R&D Ip Llc Proceso e intermedios para la preparación de compuestos de naftiridina como inhibidores de quinasa JAK
WO2017189822A1 (en) * 2016-04-28 2017-11-02 Theravance Biopharma R&D Ip, Llc Pyrimidine compounds as jak kinase inhibitors

Also Published As

Publication number Publication date
MX377180B (es) 2025-03-07
PT3433253T (pt) 2020-04-30
TW201739747A (zh) 2017-11-16
TWI726094B (zh) 2021-05-01
US20200046709A1 (en) 2020-02-13
AU2017258186B2 (en) 2020-09-17
IL262386A (en) 2018-11-29
MX2018013191A (es) 2019-02-13
EA035226B1 (ru) 2020-05-19
WO2017189822A1 (en) 2017-11-02
DK3433253T3 (da) 2020-04-06
CO2018011408A2 (es) 2018-11-13
KR102244257B1 (ko) 2021-04-26
CL2018003060A1 (es) 2018-12-14
JP6881879B2 (ja) 2021-06-02
AU2017258186A1 (en) 2018-11-15
IL262386B (en) 2021-08-31
US10028960B2 (en) 2018-07-24
US20170312280A1 (en) 2017-11-02
CA3020506A1 (en) 2017-11-02
ES2779880T3 (es) 2020-08-20
CN109071529B (zh) 2021-08-06
US10485803B2 (en) 2019-11-26
JP2019514903A (ja) 2019-06-06
SG11201809342YA (en) 2018-11-29
KR20190002591A (ko) 2019-01-08
EP3433253A1 (en) 2019-01-30
US20180303836A1 (en) 2018-10-25
CN109071529A (zh) 2018-12-21
ZA201807179B (en) 2019-08-28
EA201892436A1 (ru) 2019-04-30
EP3433253B1 (en) 2020-02-12
US11110095B2 (en) 2021-09-07

Similar Documents

Publication Publication Date Title
CO2018011408A2 (es) Compuestos de pirimidina como inhibidores de la quinasa jak
MX2020011774A (es) Compuestos de naftiridina como inhibidores de quinasa jak.
BR112019018648A2 (pt) Inibidores de jak contendo uma amida heterocíclica com 4 membros
EA202090413A1 (ru) Пиразоло- и триазолобициклические соединения в качестве ингибиторов jak киназы
MX2016015565A (es) Ciertos inhibidores de la proteina quinasa.
BR112021023824A8 (pt) Composto, composição farmacêutica, método para inibir dna-pk e uso do composto ou da composição farmacêutica
BR112017003054A2 (pt) compostos de aminopirimidinila como inibidores de jak
GEP20207202B (en) Tyrosine amide derivatives as rho-kinase inhibitors
CL2017001204A1 (es) Derivados de 6-amino-7-biciclo-7-deaza-purina como inhibidores de la proteína quinasa
UY36175A (es) 3-amino-1,5,6,7-tetrahidro-4h-indol-4-onas
BR112018008966A2 (pt) compostos inibidores de jak quinase para o tratamento de doença respiratória
UY36244A (es) Derivados de la pirimidinona como inhibidores del factor xia y/o de la calicreína plasmática y composiciones farmacéuticas que los contienen
BR112016029612A2 (pt) compostos de di-hidroisoquinolinona substituídos
CO2018005954A2 (es) Compuestos heteroaromáticos como inhibidores de btk
BR112016022069A2 (pt) Composto, composição farmacêutica, e, uso de um composto
MX374191B (es) Derivados de nucleósido sustituidos con 4´ -difluorometilo como inhibidores de la replicación de arn de la influenza.
MX2021002521A (es) Dimetilaminoazetidinaminas como inhibidores de jak.
MX395032B (es) Ciertos inhibidores de la proteína quinasa.
MX2017013874A (es) Imidazopirazinas y pirazolopirimidinas y su uso como moduladores del receptor de ampa.
EA201891319A1 (ru) Соединения алкилдигидрохинолинсульфонамида
BR112018006422A2 (pt) composições e métodos para inibir beta-lactamase
EA202192822A1 (ru) Нафтиридиновые соединения в качестве ингибиторов jak киназы
BR112018069612A2 (pt) compostos de pirroltriazina como inibidores de tam

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]

Free format text: DE ACORDO COM O ARTIGO 229-C DA LEI NO 10196/2001, QUE MODIFICOU A LEI NO 9279/96, A CONCESSAO DA PATENTE ESTA CONDICIONADA A ANUENCIA PREVIA DA ANVISA. CONSIDERANDO A APROVACAO DOS TERMOS DO PARECER NO 337/PGF/EA/2010, BEM COMO A PORTARIA INTERMINISTERIAL NO 1065 DE 24/05/2012, ENCAMINHA-SE O PRESENTE PEDIDO PARA AS PROVIDENCIAS CABIVEIS.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]
B06W Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette]
B350 Update of information on the portal [chapter 15.35 patent gazette]
B11B Dismissal acc. art. 36, par 1 of ipl - no reply within 90 days to fullfil the necessary requirements